Kirsten L. Greene, MD, MAS, FACS, discusses the future of personalized therapy in prostate cancer.
Kirsten L. Greene, MD, MAS, FACS, associate chief medical officer, Paul Mellon Professor and Chair, UVA Department of Urology, UVA Health, discusses the future of personalized therapy in prostate cancer.
Future research efforts in prostate cancer should focus on finding new ways to eradicate the disease without using invasive or destructive modalities, such as surgery or radiation therapy, Greene says.
However, personalized therapy is still largely investigational in the space, says Greene. Perhaps, tagging prostate-specific membrane antigen with a radiopharmaceutical, cellular poison, or an immune-stimulating agent could further the role of precision medicine for patients.
Strategies such as this could decrease the need for prostatectomy in men with newly diagnosed, metastatic, or recurrent disease, concludes Greene.